Challenges for the application of DNA methylation biomarkers in molecular diagnostic testing for cancer

Expert Review of Molecular Diagnostics

Volumn 13, Issue 3, 2013, Pages 283-294

  Jain, Surbhi ^a   Wojdacz, Tomasz K ^b   Su, Ying Hsiu ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

biomarkers; cancer detection; DNA methylation; molecular diagnostic testing

Indexed keywords

DNA METHYLTRANSFERASE; GLUTATHIONE TRANSFERASE P1; VIMENTIN;

CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SCREENING; CARCINOGENESIS; CPG ISLAND; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA BASE COMPOSITION; DNA ISOLATION; DNA MARKER; DNA METHYLATION; DNA MODIFICATION; DNA SEQUENCE; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; GENOME; HIGH RISK POPULATION; MOLECULAR DIAGNOSIS; MOLECULAR WEIGHT; NEOPLASM; POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; STANDARDIZATION; TISSUE DIFFERENTIATION; TUMOR SUPPRESSOR GENE; X CHROMOSOME INACTIVATION;

ANIMALS; CPG ISLANDS; DNA; DNA METHYLATION; EARLY DETECTION OF CANCER; GENES, NEOPLASM; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; ORGAN SPECIFICITY; REFERENCE STANDARDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84876122007     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.13.9     Document Type: Review

References (90)

1. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 61(8), 3225-3229 (2001
2. Wood LD, Parsons DW, Jones S et al. The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 1108-1113 (2007
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415-428 (2002
4. Shen J, Wang S, Zhang YJ et al. Genomewide DNA methylation profiles in hepatocellular carcinoma. Hepatology 55(6), 1799-1808 (2012
5. Guichard C, Amaddeo G, Imbeaud S et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44(6), 694-698 (2012
6. Mikeska T, Bock C, Do H, Dobrovic A. DNA methylation biomarkers in cancer: progress towards clinical implementation. Expert Rev. Mol. Diagn. 12(5), 473-487 (2012
7. Straussman R, Nejman D, Roberts D et al. Developmental programming of CpG island methylation profiles in the human genome. Nat. Struct. Mol. Biol. 16(5), 564-571 (2009
8. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, Feinberg AP. Relaxation of imprinted genes in human cancer. Nature 362(6422), 747-749 (1993
9. Ogawa O, Eccles MR, Szeto J et al. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362(6422), 749-751 (1993
10. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim. Biophys. Acta 1775(1), 138-162 (2007
11. Baylin SB. DNA methylation and gene silencing in cancer. Nat. Clin. Pract. Oncol. 2(Suppl. 1), S4-S11 (2005
12. Homma N, Tamura G, Honda T et al. Spreading of methylation within RUNX3 CpG island in gastric cancer. Cancer Sci. 97(1), 51-56 (2006
13. Buffart TE, Overmeer RM, Steenbergen RD et al. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer. Br. J. Cancer 99(11), 1802-1807 (2008
14. Gigek CO, Leal MF, Silva PN et al. hTERT methylation and expression in gastric cancer. Biomarkers 14(8), 630-636 (2009
15. Deng G, Chen A, Hong J, Chae HS, Kim YS. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 59(9), 2029-2033 (1999
16. Yoshikawa H, Matsubara K, Qian GS et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 28(1), 29-35 (2001
17. Jain S, Yoon SY, Zhu L et al. Arf4 determines dentate gyrus-mediated pattern separation by regulating dendritic spine development. PLoS ONE 7(9), e46340 (2012
18. Jain S, Chang TT, Hamilton JP et al. Methylation of the CpG sites only on the sense strand of the APC gene is specific for hepatocellular carcinoma. PLoS ONE 6(11), e26799 (2011
19. van Vlodrop IJ, Niessen HE, Derks S et al. Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin. Cancer Res. 17(13), 4225-4231 (2011
20. Millar DS, Paul CL, Molloy PL, Clark SJ. A distinct sequence (ATAAA)n separates methylated and unmethylated domains at the 5́-end of the GSTP1 CpG island. J. Biol. Chem. 275(32), 24893-24899 (2000
21. Di Gioia S, Bianchi P, Destro A et al. Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver. BMC Cancer 6, 89 (2006
22. Yeo W, Wong N, Wong WL, Lai PB, Zhong S, Johnson PJ. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int. 25(2), 266-272 (2005
23. Um TH, Kim H, Oh BK et al. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J. Hepatol. 54(5), 939-947 (2011
24. Yan PS, Shi H, Rahmatpanah F et al. Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. Cancer Res. 63(19), 6178-6186 (2003
25. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 9(6), 465-476 (2008
26. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 16(1), 6-21 (2002
27. Illingworth R, Kerr A, Desousa D et al. A novel CpG island set identifies tissuespecific methylation at developmental gene loci. PLoS Biol. 6(1), e22 (2008
28. Eckhardt F, Lewin J, Cortese R et al. DNA methylation profiling of human chromo- somes 6, 20 and 22. Nat. Genet. 38(12), 1378-1385 (2006
29. Song F, Mahmood S, Ghosh S et al. Tissue specific differentially methylated regions (TDMR): changes in DNA methylation during development. Genomics 93(2), 130-139 (2009
30. Portela A, Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol. 28(10), 1057-1068 (2010
31. Hosoya K, Yamashita S, Ando T, Nakajima T, Itoh F, Ushijima T. Adenomatous polyposis coli 1A is likely to be methylated as a passenger in human gastric carcinogenesis. Cancer Lett. 285(2), 182-189 (2009
32. Dobrovic A, Kristensen LS. DNA methylation, epimutations and cancer predisposition. Int. J. Biochem. Cell Biol. 41(1), 34-39 (2009
33. Wojdacz TK, Thestrup BB, Cold S, Overgaard J, Hansen LL. No difference in the frequency of locus-specific methylation in the peripheral blood DNA of women diagnosed with breast cancer and age-matched controls. Future Oncol. 7(12), 1451-1455 (2011
34. Snell C, Krypuy M, Wong EM, Loughrey MB, Dobrovic A; kConFab investigators. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. Breast Cancer Res. 10(1), R12 (2008
35. Chai H, Brown RE. Field effect in cancer - an update. Ann. Clin. Lab. Sci. 39(4), 331-337 (2009
36. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 47(3), 908-918 (2008
37. Sherman M. Recurrence of hepatocellular carcinoma. N. Engl. J. Med. 359(19), 2045-2047 (2008
38. Yang JD, Nakamura I, Roberts LR. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin. Cancer Biol. 21(1), 35-43 (2011
39. Giovannucci E, Ogino S. DNA methylation, field effects, and colorectal cancer. J. Natl Cancer Inst. 97(18), 1317-1319 (2005
40. Hoshida Y, Villanueva A, Llovet JM. Molecular profiling to predict hepatocellular carcinoma outcome. Expert Rev. Gastroenterol. Hepatol. 3(2), 101-103 (2009
41. Toyota M, Ahuja N, Suzuki H et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 59(21), 5438-5442 (1999
42. Viet CT, Schmidt BL. Methylation array analysis of preoperative and postoperative saliva DNA in oral cancer patients. Cancer Epidemiol. Biomarkers Prev. 17(12), 3603-3611 (2008
43. Reinert T, Modin C, Castano FM et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin. Cancer Res. 17(17), 5582-5592 (2011
44. Cairns P, Esteller M, Herman JG et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. 7(9), 2727-2730 (2001
45. Cairns P. Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Ann. NY Acad. Sci. 1022, 40-43 (2004
46. de Fraipont F, Moro-Sibilot D, Michelland S, Brambilla E, Brambilla C, Favrot MC. Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer? Lung Cancer 50(2), 199-209 (2005
47. Lee A, Kim Y, Han K, Kang CS, Jeon HM, Shim SI. Detection of tumor markers including carcinoembryonic antigen, APC, and cyclin D2 in fine-needle aspiration fluid of breast. Arch. Pathol. Lab. Med. 128(11), 1251-1256 (2004
48. Lind GE, Danielsen SA, Ahlquist T et al. Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol. Cancer 10, 85 (2011
49. Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker - a critical appraisal of the literature. Clin. Chim. Acta 411(21-22), 1611-1624 (2010
50. Schwarzenbach H, Chun FK, Isbarn H, Huland H, Pantel K. Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients. J. Cancer Res. Clin. Oncol. 137(5), 811-819 (2011
51. Chan KC, Lai PB, Mok TS et al. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin. Chem. 54(9), 1528-1536 (2008
52. Wong IH, Zhang J, Lai PB, Lau WY, Lo YM. Quantitative analysis of tumorderived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. Clin. Cancer Res. 9(3), 1047-1052 (2003
53. Tsutsui M, Iizuka N, Moribe T et al. Methylated cyclin D2 gene circulating in the blood as a prognosis predictor of hepatocellular carcinoma. Clin. Chim. Acta 411(7-8), 516-520 (2010
54. Kirk GD, Lesi OA, Mendy M et al. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma. Oncogene 24(38), 5858-5867 (2005
55. Warren JD, Xiong W, Bunker AM et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med. 9, 133 (2011
56. Su YH, Wang M, Aiamkitsumrit B, Brenner DE, Block TM. Detection of a K-ras mutation in urine of patients with colorectal cancer. Cancer Biomark. 1(2-3), 177-182 (2005
57. Su YH, Song J, Wang Z et al. Removal of high-molecular-weight DNA by carboxylated magnetic beads enhances the detection of mutated K-ras DNA in urine. Ann. NY Acad. Sci. 1137, 82-91 (2008
58. Su YH, Wang M, Brenner DE et al. Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J. Mol. Diagn. 6(2), 101-107 (2004
59. Su YH, Wang M, Brenner DE, Norton PA, Block TM. Detection of mutated K-ras DNA in urine, plasma, and serum of patients with colorectal carcinoma or adenomatous polyps. Ann. NY Acad. Sci. 1137, 197-206 (2008
60. Melkonyan HS, Feaver WJ, Meyer E et al. Transrenal nucleic acids: from proof of principle to clinical tests. Ann. NY Acad. Sci. 1137, 73-81 (2008
61. Chan AK, Chiu RW, Lo YM; Clinical Sciences Reviews Committee of the Association of Clinical Biochemists. Cell-free nucleic acids in plasma, serum and urine: a new tool in molecular diagnosis. Ann. Clin. Biochem. 40(Pt 2), 122-130 (2003
62. Serdyuk OI, Botezatu IV, Shelepov VP et al. Detection of mutant k-ras sequences in the urine of cancer patients. Bull. Exp. Biol. Med. 131(3), 283-284 (2001
63. Botezatu I, Serdyuk O, Potapova G et al. Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin. Chem. 46(8 Pt 1), 1078-1084 (2000
64. Lichtenstein AV, Melkonyan HS, Tomei LD, Umansky SR. Circulating nucleic acids and apoptosis. Ann. NY Acad. Sci. 945, 239-249 (2001
65. Jahr S, Hentze H, Englisch S et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61(4), 1659-1665 (2001
66. Lin SY, Dhillon V, Jain S et al. A locked nucleic acid clamp-mediated PCR assay for detection of a p53 codon 249 hotspot mutation in urine. J. Mol. Diagn. 13(5), 474-484 (2011
67. Song BP, Jain S, Lin SY et al. Detection of hypermethylated vimentin in urine of patients with colorectal cancer. J. Mol. Diagn. 14(2), 112-119 (2012
68. Lin SL, Jain S, Song W, Hu C-T, Su Y-H. Strategic assay developments for detection of HBV 1762T/1764A double mutation in urine of patients with HBV-associated hepatocellular carcinomas. Lau W-Y (Ed.). In: Hepatocellular Carcinoma - Clinical Research. InTech, Rijeka, Croatia, 139-154 (2012
69. Diehl F, Schmidt K, Durkee KH et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 135(2), 489-498 (2008
70. Chan KC, Leung SF, Yeung SW, Chan AT, Lo YM. Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients. Clin. Cancer Res. 14(15), 4809-4813 (2008
71. Shekhtman EM, Anne K, Melkonyan HS, Robbins DJ, Warsof SL, Umansky SR. Optimization of transrenal DNA analysis: detection of fetal DNA in maternal urine. Clin. Chem. 55(4), 723-729 (2009
72. Sikora A, Zimmermann BG, Rusterholz C et al. Detection of increased amounts of cell-free fetal DNA with short PCR amplicons. Clin. Chem. 56(1), 136-138 (2010
73. Mao R, Chou LS. Methylation analysis by restriction endonuclease digestion and real-time PCR. Clin. Chem. 56(7), 1050-1052 (2010
74. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylationspecific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93(18), 9821-9826 (1996
75. Aggerholm A, Hokland P. DAP-kinase CpG island methylation in acute myeloid leukemia: methodology versus biology? Blood 95(9), 2997-2999 (2000
76. Rand K, Qu W, Ho T, Clark SJ, Molloy P. Conversion-specific detection of DNA methylation using real-time polymerase chain reaction (ConLight-MSP) to avoid false positives. Methods 27(2), 114-120 (2002
77. Dobrovic A. Methods for analyses of DNA methylation. In: Molecular Diagnostics for the Clinical Laboratorian. Coleman WB, Tsongalis GJ (Eds). Humana Press, NJ, USA, (2005
78. Wojdacz TK. Methylation-sensitive high-resolution melting in the context of legislative requirements for validation of analytical procedures for diagnostic applications. Expert Rev. Mol. Diagn. 12(1), 39-47 (2012
79. Warnecke PM, Stirzaker C, Melki JR, Millar DS, Paul CL, Clark SJ. Detection and measurement of PCR bias in quantitative methylation analysis of bisulphitetreated DNA. Nucleic Acids Res. 25(21), 4422-4426 (1997
80. Wojdacz TK, Hansen LL. Reversal of PCR bias for improved sensitivity of the DNA methylation melting curve assay. BioTechniques 41(3), 274, 276, 278 (2006
81. Wojdacz TK, Hansen LL, Dobrovic A. A new approach to primer design for the control of PCR bias in methylation studies. BMC Res. Notes 1, 54 (2008
82. Wojdacz TK, Borgbo T, Hansen LL. Primer design versus PCR bias in methylation independent PCR amplifications. Epigenetics 4(4), 231-234 (2009
83. Eads CA, Danenberg KD, Kawakami K et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 28(8), E32 (2000
84. Wojdacz TK, Moller TH, Thestrup BB, Kristensen LS, Hansen LL. Limitations and advantages of MS-HRM and bisulfite sequencing for single locus methylation studies. Expert Rev. Mol. Diagn. 10(5), 575-580 (2010
85. Candiloro IL, Mikeska T, Dobrovic A. Assessing combined methylation-sensitive high resolution melting and pyrosequencing for the analysis of heterogeneous DNA methylation. Epigenetics 6(4), 500-507 (2011
86. Wojdacz TK. The limitations of locus specific methylation qualification and quantification in clinical material. Front. Genet. 3, 21 (2012
87. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK). Eur. J. Cancer 41(12), 1690-1696 (2005
88. Fan HC, Gu W, Wang J, Blumenfeld YJ, El-Sayed YY, Quake SR. Non-invasive prenatal measurement of the fetal genome. Nature 487(7407), 320-324 (2012
89. Standards for the Reporting of Diagnostic Accuracy Studies. www.stard-statement.org
90. Early Detection Research Network. http://edrn.nci.nih.gov